APA (7th ed.) Citation

Y, T., K, H., Y, M., Y, I., T, I., K, U., . . . H, K. (2026). Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: A 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J). RMD open, 12(2), . https://doi.org/10.1136/rmdopen-2025-006446

Chicago Style (17th ed.) Citation

Y, Tanaka, et al. "Real-world Effectiveness, Safety and Patient-reported Outcomes of Sarilumab in Patients with Rheumatoid Arthritis: A 52-week, Prospective, Open-label, Non-interventional, Observational, Nationwide, Large-cohort Study in Japan (PROFILE-J)." RMD Open 12, no. 2 (2026). https://doi.org/10.1136/rmdopen-2025-006446.

MLA (9th ed.) Citation

Y, Tanaka, et al. "Real-world Effectiveness, Safety and Patient-reported Outcomes of Sarilumab in Patients with Rheumatoid Arthritis: A 52-week, Prospective, Open-label, Non-interventional, Observational, Nationwide, Large-cohort Study in Japan (PROFILE-J)." RMD Open, vol. 12, no. 2, 2026, https://doi.org/10.1136/rmdopen-2025-006446.